AbbVie

Open: 162.75 Close: 162.4 Change: -0.35

You don't have read the whole internet to decide whether to invest in AbbVie. Use an AI.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Inc, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. is one of the stocks most watched by Zacks.com visitors lately. The company is expected to post earnings of $2.93 per share in the current quarter. CVS Health said on Wednesday it will remove Abbvies blockbuster rheumatoid arthritis drug Humira.

Today's News

AbbVie Inc. (abbvie inc. (ABBV) stock price, quote, news & analysis. Join now Search for Symbols, analysts, keywords Log in ABBV and Log in. AbbVie is committed to operating with integrity, driving innovation, transforming lives, serving our community, and embracing diversity and inclusion. The National Field Trainer – GIC is responsible for facilitating training programs. On 9 January 2024, AbbVie announced the launch of Produodopa (foscarbidopa/foslevodopa) in the EU, to treat severe motor fluctuations in patients with advanced Parkinsons disease (PD) Go deeper with GlobalData Reports. AbbVie acquires Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline. $8.7B Cerevel acquisition to Bolster Neuro pipeline. $10.1 billion ImmunoGen buy and Altimmunes Phase II win demonstrate that the antibody-drug conjugate market is red hot. AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. AbbVie has signed exclusive option and license agreements with Umoja Biopharma to develop multiple, in-situ generated CAR-T cell therapy candidates in #oncology. P2P Business Partner Specialist - Eyecare Primary Mascot, Australia. AbbVie Inc. spent $351.1 million on TV ads for Rinvoq in 2022, knocking last years winner Dupixent into 2nd place. In 2023, the tables turned as Skyrizi took the lead, with Abbvie allocating a substantial total of $383.7 million across its advertisements throughout the year. AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The first agreement provides Abbvie an exclusive option to license Umoja Biopharma CAR-T cell therapy candidates. AbbVie is recruiting for a Sr. senior scientist ii, drug substance development at abbvie. Senior Scientist II, Drug Substance Development at ABBVIE. The company is grappling with losing Humiras patent protection. AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. In 2022, Abbvies revenue was $58.05 billion, an increase of 3.30% compared to the previous years $56.20 billion. Price Target $169.0 (4.06% upside) Analyst Consensus: Buy stock. CVS Health said on Wednesday it will remove AbbVies blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1. Abbvie will present at the 42nd Annual J.P. 2, 2024 event. ImmunoGen Sued Over Alleged Omissions in AbbVie Buyout Proxy by Ben Miller. Director allegedly left several key details out of a proxy statement for the proposed acquisition. AbbVie, Inc. senior pricing analyst, government programs at abbvie. Apply Now. AbbVie Inc. is one of the stocks most watched by Zacks.com visitors lately. The company is expected to post earnings of $2.93 per share in the current quarter, indicating a change of -18.6% from the year-ago quarter.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Inc, stock, abbvie, ABBV, company, year, and the most common words in the summary are: abbvie, stock, market, dividend, top, job, news, . One of the sentences in the summary was: is one of the stocks most watched by Zacks.com visitors lately. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #dividend #top #job #news.